Thrive Wealth Management LLC Purchases Shares of 32,000 Caribou Biosciences, Inc. (NASDAQ:CRBU)

Thrive Wealth Management LLC acquired a new stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 32,000 shares of the company’s stock, valued at approximately $51,000.

Other institutional investors also recently modified their holdings of the company. Renaissance Technologies LLC purchased a new position in Caribou Biosciences during the 2nd quarter valued at about $2,432,000. Dimensional Fund Advisors LP increased its stake in shares of Caribou Biosciences by 25.7% during the second quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock valued at $4,302,000 after buying an additional 536,162 shares during the period. PFM Health Sciences LP increased its stake in shares of Caribou Biosciences by 5.5% during the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after buying an additional 223,299 shares during the period. XTX Topco Ltd bought a new position in shares of Caribou Biosciences during the second quarter valued at approximately $341,000. Finally, Geode Capital Management LLC lifted its stake in Caribou Biosciences by 6.5% in the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after acquiring an additional 124,782 shares during the period. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

Caribou Biosciences Price Performance

NASDAQ:CRBU opened at $1.53 on Tuesday. The firm has a market capitalization of $138.54 million, a P/E ratio of -0.93 and a beta of 2.34. Caribou Biosciences, Inc. has a one year low of $1.50 and a one year high of $8.33. The company’s 50-day simple moving average is $1.88 and its 200 day simple moving average is $2.00.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The firm had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million. On average, equities research analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on CRBU. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a report on Friday, November 15th. Citigroup decreased their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. Finally, Bank of America cut their price objective on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Caribou Biosciences has an average rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.